Literature DB >> 20201556

Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases.

Marie Lopez1, Laurent F Bornaghi, Alessio Innocenti, Daniela Vullo, Susan A Charman, Claudiu T Supuran, Sally-Ann Poulsen.   

Abstract

The contribution of membrane-bound carbonic anhydrases (CAs) to hypoxic tumor growth and progression in cancer implicates cancer-associated CAs as a promising drug target for oncology. In this paper, we present a new class of sulfonamide-linked neoglycoconjugate that was designed to selectively target and inhibit the extracellular domains of the cancer-relevant CA isozymes. We describe the application of novel, yet straightforward, chemistry toward the synthesis of inhibitors that comprise both S-glycosyl sulfenamides and S-glycosyl sulfonamides. We also present the CA inhibition profile of our new neoglycoconjugates, more specifically a library of 30 compounds (3-32) that were designed to optimize both SAR (structure-activity relationship) and SPR (structure-property relationship) characteristics. We show that our approach produces neutral, water-soluble, and potent inhibitors (K(i)s in the low nanomolar range) that target cancer-associated CAs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20201556     DOI: 10.1021/jm901888x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo.

Authors:  Fabrizio Carta; Mayank Aggarwal; Alfonso Maresca; Andrea Scozzafava; Robert McKenna; Emanuela Masini; Claudiu T Supuran
Journal:  J Med Chem       Date:  2012-02-13       Impact factor: 7.446

2.  An efficient strategy to enhance binding affinity and specificity of a known isozyme inhibitor.

Authors:  Joo-Eun Jee; Jaehong Lim; Yong Siang Ong; Jessica Oon; Liqian Gao; Hak Soo Choi; Su Seong Lee
Journal:  Org Biomol Chem       Date:  2016-07-12       Impact factor: 3.876

3.  Structural insights into carbonic anhydrase IX isoform specificity of carbohydrate-based sulfamates.

Authors:  Janina Moeker; Brian P Mahon; Laurent F Bornaghi; Daniela Vullo; Claudiu T Supuran; Robert McKenna; Sally-Ann Poulsen
Journal:  J Med Chem       Date:  2014-10-08       Impact factor: 7.446

4.  P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors.

Authors:  Joanna Kopecka; Gregory M Rankin; Iris C Salaroglio; Sally-Ann Poulsen; Chiara Riganti
Journal:  Oncotarget       Date:  2016-12-27

Review 5.  Targeting carbonic anhydrase IX activity and expression.

Authors:  Brian P Mahon; Melissa A Pinard; Robert McKenna
Journal:  Molecules       Date:  2015-01-30       Impact factor: 4.411

6.  An overview of carbohydrate-based carbonic anhydrase inhibitors.

Authors:  Doretta Cuffaro; Elisa Nuti; Armando Rossello
Journal:  J Enzyme Inhib Med Chem       Date:  2020-10-20       Impact factor: 5.051

7.  5,11-Ditosyl-5H,11H-dibenzo[b,f][1,5]diazo-cine-6,12-dione acetic acid hemisolvate.

Authors:  Najat Abbassi; Oulemda Bassou; El Mostapha Rakib; Mohamed Saadi; Lahcen El Ammari
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-03-28

8.  N-(2-Allyl-4-chloro-2H-indazol-5-yl)-4-meth-oxy-benzene-sulfonamide hemi-hydrate.

Authors:  Hakima Chicha; Assoman Kouakou; El Mostapha Rakib; Mohamed Saadi; Lahcen El Ammari
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-07-31

9.  4-Methyl-N-(1-methyl-1H-indazol-5-yl)benzene-sulfonamide.

Authors:  Hakima Chicha; Bassou Oulemda; El Mostapha Rakib; Mohamed Saadi; Lahcen El Ammari
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-08-23

10.  Intrinsic Thermodynamics and Structure Correlation of Benzenesulfonamides with a Pyrimidine Moiety Binding to Carbonic Anhydrases I, II, VII, XII, and XIII.

Authors:  Miglė Kišonaitė; Asta Zubrienė; Edita Capkauskaitė; Alexey Smirnov; Joana Smirnovienė; Visvaldas Kairys; Vilma Michailovienė; Elena Manakova; Saulius Gražulis; Daumantas Matulis
Journal:  PLoS One       Date:  2014-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.